Continuous improvement on the rationality of prophylactic injectable PPIs usage by a clinical pharmacist-led guidance team at a Chinese tertiary teaching hospital
Authors:
Open Access
- 12 October 2020
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 48 (10)
Abstract
Objective: We aimed to evaluate the effects of a clinical pharmacist-led-guidance-team (CPGT) on improving rational prophylactic injectable proton pump inhibitor use (PIPU) and to explore the application of the Plan–Do–Check–Act (PDCA) method in promoting rational PIPU. Methods: We conducted a retrospective study among 814 patients at a Chinese tertiary teaching hospital from January 2017 to December 2018. We enrolled 98 patients before the PDCA; 297 and 419 patients were included in first- and second-round PDCA cycles, respectively. The CPGT established the criteria for PIPU and conducted interventions, including medical record reviews, provision of feedback, clinician education, and outcome analysis. We analyzed the appropriateness and costs of PIPU before and after establishment of the PDCA cycle. Results: Implementation of continuous CPGT-led intervention and a PDCA cycle significantly decreased the rate of irrational PIPU (53.06% vs. 8.57%), including duration, administration route, indication, and dosing frequency. Costs of total (USD 211.28 ± 162.33 vs. 53.17 ± 22.32) and inappropriate (USD 76.70 ± 59.78 vs. 2.25 ± 3.86) PIPU per patient were significantly reduced. The target compliance rate was 107.56%. Conclusion: A CPGT can have an effective role in improving rational PIPU and optimizing administration through a PDCA cycle, to attain improved clinical and economic outcomes.Keywords
Funding Information
- Medical and Health Science and Technology Project of Zhejiang Province (2018KY402)
- Zhejiang Provincial Natural Science Foundation of China (YY20H300003)
This publication has 33 references indexed in Scilit:
- Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospitalBMC Health Services Research, 2018
- Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysisWorld Journal of Gastroenterology, 2017
- Adverse effects of proton-pump inhibitor use in older adults: a review of the evidenceTherapeutic Advances in Drug Safety, 2017
- Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injuryKidney International, 2017
- Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trialsCritical Care, 2016
- Application of propensity scores to estimate the association between government subsidy and injection use in primary health care institutions in ChinaBMC Health Services Research, 2013
- Overutilization of proton-pump inhibitors: what the clinician needs to knowTherapeutic Advances in Gastroenterology, 2012
- Proton pump inhibitors: an update of their clinical use and pharmacokineticsEuropean Journal of Clinical Pharmacology, 2008
- Intravenous proton pump inhibitor therapy: a rationale for use.2005
- Stress ulcer prophylaxis in the postoperative periodAmerican Journal of Health-System Pharmacy, 2004